Journey Medical Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

INTANGIBLES (Tables)

v3.21.2

INTANGIBLES (Tables)

9 Months Ended

Sep. 30, 2021

INTANGIBLES

Schedule of intangible assets


	Estimated Useful
($in thousands)	Lives (Years)	September 30, 2021		December 31, 2020
		(Unaudited)
Ceracade^®	3	$	300	$	300
Luxamend^®	3		50		50
Targadox^®	3		1,250		1,250
Ximino^®	7		7,134		7,134
Exelderm^®	3		1,600		1,600
Accutane	5		4,727		4,727
Anti-itch product ⁽¹⁾	3		3,942		3,945
Total intangible assets			19,003		19,006
Accumulated amortization			(5,960)		(3,977)
Net intangible assets		$	13,043	$	15,029

(1)	As of September 30, 2021, this asset has not yet been placed in service, therefore no amortization expense was recognized on this asset for the three or nine months ended September 30, 2021. Commercial launch of this product is expected in the first half of 2022.

Schedule of intangible assets roll forward


	Intangible
($in thousands)	Assets, Net
Beginning balance at January 1, 2021	$	15,029
Reductions:
Anti-itch Product license acquisition adjustment		(3)
Amortization expense		(1,983)
Ending balance at September 30, 2021	$	13,043

Schedule of future amortization of intangible assets


					Total
($in thousands)	Ximino®		Accutane®		Amortization
Three months ending December 31, 2021	$	255	$	236	$	491
Year ended December 31, 2022		1,019		946		1,965
Year ended December 31, 2023		1,019		945		1,964
Year ended December 31, 2024		1,019		946		1,965
Year ended December 31, 2025		1,019		945		1,964
Thereafter		595		157		752
Sub-total	$	4,926	$	4,175	$	9,101
Assets not yet placed in service:
Anti-itch product license acquisition		—		—		3,942
Total	$	4,926	$	4,175	$	13,043

- Definition

Tabular disclosure of roll forward of finite lived intangible assets.

+ References

No definition available.

+ Details

Name:	derm_ScheduleOfFiniteLivedIntangibleAssetsRollForwardTableTextBlock
Namespace Prefix:	derm_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.

+ References

+ Details

Name:	us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration